Membranous Nephropathy - Dr. Fervenza (Rochester)

⇓ ⇓ ⇓ ⇓ ⇓ ⇓ ⇓ ⇓ ⇓ ⇓ WEITERE INFOS UND LINKS ⇓ ⇓ ⇓ ⇓ ⇓ ⇓ ⇓ ⇓ ⇓ ⇓
Dr. Fernando Fervenza discusses pathophysiology, diagnosis and treatment of membranous nephropathy. Dr. Fervenza is the lead investigator of the MENTOR study, which is the pivotal randomized trial that studied rituximab in membranous nephropathy, and he is co-author of the 2021 KDIGO guidelines on glomerulonephritis.
Further information can be found at:
H Deblec et al.
Antenatal Membranous Glomerulonephritis Due to Anti-Neutral Endopeptidase Antibodies
www.nejm.org/d...
LH Beck et al.
M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy
www.nejm.org/d...
NM Thomas et al.
Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy
www.nejm.org/d...
S Sethi
New ‘Antigens’ in Membranous Nephropathy
jasn.asnjourna...
C Ponticelli et al.
A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.
jasn.asnjourna...
P Ruggenenti et al.
Rituximab in Idiopathic Membranous Nephropathy
jasn.asnjourna...
DJ Salent
Genetic Variants in Membranous Nephropathy: Perhaps a Perfect Storm Rather than a Straightforward Conformeropathy?
jasn.asnjourna...
SA Bobart et al.
Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies
www.kidney-int...
FC Fervenza et al.
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy
www.nejm.org/d...